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Abstract 
Since oral squamous cell carcinoma (OSCC) is the most prevalent malignant cancer in the oral cavity, several 
researches have been performed to study the role of important enzymes in this disease. Among them, the ma-
trix metalloproteinases (MMPs) are highlighted, due to the fact that they are proteinases responsible to degrade 
many extra-cellular matrix components, making possible the invasion of neoplasic cells. Important tools in cancer 
prognosis have been utilized aiming to correlate high levels of MMPs and OSCC, such as immunohistochemical, 
zymographic and mRNA detection methods. However, these techniques are usually applied after cancer detection, 
characterizing a curative but not a preventive medicine. Trying to make interventions before the development of 
the disease and making possible the identification of people at high risk and, analysis of modifications in MMP 
genes has been a chance for modern medicine. Recently, polymorphisms in MMP genes have been related to diffe-
rent neoplasias, including OSCC. Despite investigation is beginning, MMP gene polymorphisms seems to have a 
promising future in oral cancer research and some of the present results have shown that there are MMP polymor-
phisms related to an increased risk for developing oral cancer.
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Introduction
For years, research groups have been working on eva-
luating the presence, activity, function and regulation of 
matrix metalloproteinases (MMPs) in healthy and di-
seased oral tissues (1). Today, a new era in oral health 
professional education is the study and application of 
human genetic variance during normal development, 
diseases, disorders, and responses to treatments and the-
rapeutics (2). 
- The Matrix Metalloproteinases (MMPs)
The MMPs group is represented by more than 20 human 
enzymes (3,4) which require presence of zinc to realize 
their functions. These proteases are classified based not 
only on the structural domain and organization, but also 
on the substance that can be degraded by them (5). The 
main MMP classes are: collagenases, gelatinases, stro-
melysins, and the membrane-type MMPs (MT-MMP) 
(6). 
The collagenases are the MMPs-1, -8 and -13, known as 
collagenases 1, 2 and 3 respectively, mainly degrading 
type I, II and III collagen (4,7). In addition, the MMPs-2 
and -9, also called gelatinases A and B respectively, de-
grade preferentially gelatin (denatured collagen) and 
type IV collagen (4,8) while the stromelysins 1 and 2 
(MMPs-3 and -10) are able to act on non collagen ma-
trix proteins, such as fibronectin (7,8). Finally, the last 
subgroup, the MT-MMPs, is numbered from 1 to 6: 
MT1-MMP, MT2-MMP, MT3-MMP, MT4-MMP, MT5-
MMP and MT6-MMP, corresponding in order to MMPs-
14, -15, -16, -17, -24 and -25. The MT-MMPs present an 
important action on the activation of other MMPs and 
each subtype is responsible for the degradation of diffe-
rent extra-cellular matrix components (4,8). 
Usually health tissues present low expression of activated 
MMPs (6), in contrast, an increase in MMPs expression 
has been related to malignant neoplasias, demonstrating 
noticeable significance in proteolytic action during the 
invasion and metastasis processes (4-6). 
Oral Cancer and MMPs tissue levels
Oral squamous cell carcinoma (OSCC) is the most pre-
valent malignant cancer in oral cavity (9). Despite the 
histopathology is being the most frequent technique 
used by pathologists to identify, analyze and rank the 
clinical phenotype of human cancers, this method may 
present reservations. Multiple patients with squamous 
cell carcinoma may provide biopsy samples that closely 
resemble one another; however, they may present diffe-
rent neoplasic disease, responses to therapy and clinical 
outcomes (2). 
Trying to complete the diagnosis, the MMP detection in 
the tissue has been investigated using techniques such 
as immunohistochemistry (10, 11), zymography (10,12) 
and RNA analysis (13). 
Studies have shown that OSCC cases seem to express 
higher levels of different MMPs when compared to nor-
mal tissues (13). 
The MMPs expression in oral cancer tissue is an impor-
tant tool in cancer prognosis. However, MMP expres-
sion only became substantial if the tests are performed 
after cancer initiation. Due to this fact, this methodology 
might be used for therapeutic purposes, but not as a pre-
ventive tool, which is the idea of new medicine.
To proteins be expressed in the tissue, their codification 
must be done based on information coming from the 
DNA code. If there is an alteration in the gene, it is pos-
sible to have a modification in this process, resulting in 
different MMP protein expressions in the tissue. Thus, 
the genetic control is particularly important in these re-
gulations and if alterations, as a gene polymorphism, are 
found, they might determine a different cancer clinico-
pathological development.
Oral cancer and MMPs gene polymorphisms 
Genotyping MMPs as potential markers for susceptibi-
lity to oral cancer might allow a precise and early iden-
tification of individuals at high risk. These findings may 
help not only prediction and prevention, but also the 
plan of therapeutic methods and evaluation of treatment 
outcome (14)
Despite numerous genetic studies have correlated MMP 
gene polymorphisms  and several categories of neopla-
sias (15-24), few authors have studied the link between 
MMP gene polymorphisms and oral cancer development 
(9,14,25).
The genetic polymorphisms are characterized by a mo-
dification in the DNA base pairs sequence in more than 
1% of the human population. The majority of these al-
terations are probably functionally neutral; however, the 
polymorphism may be linked on the regulation of gene 
expression or function of the coded protein influencing 
different biological behaviors and susceptibility to di-
seases (3). Approximately, ninety percent of DNA poly-
morphisms are single nucleotide polymorphisms (SNP) 
due to single base exchange.
In the gene, the region responsible for the transcription 
control is the gene promoter, located upstream from 
transcription start site and contains sequences for the 
binding of critical transcriptional factors. In recent ti-
mes, several DNA polymorphisms were found in the 
promoter region of various MMPs (3). Particularly in 
oral cancer, the studies are related to MMP-1, -2, -3 and 
-9 polymorphisms.
- MMP-1 gene polymorphism
There is a MMP-1 genetic polymorphism which is a pro-
mising candidate for susceptibility to cancers (26). This 
polymorphism in MMP-1 gene promoter is characteri-
zed by insertion/deletion of a guanine at position –1607 
and formation of two different alleles, one having a sin-
gle guanine (1G) and the other having two guanine (2G) 
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(27). The cells expressing the 2G polymorphism seem 
to present a more aggressive matrix degradation system, 
possibly facilitating cancer development (27). The fre-
quency of the 2G/2G genotype is significantly higher 
in patients presenting colorectal cancer (16), renal cell 
carcinoma (19) and head and neck squamous cell carci-
noma (28) than in controls. 
In addition, the presence of this polymorphism (2G) has 
been associated not only with an increased risk of local 
invasiveness in cutaneous malignant melanoma (15) and 
cervical cancer (22), but also with worse cancer specific 
survival in colorectal cancer (29) and the risk for the de-
velopment of metastasis in breast cancer (24). 
In oral cancer, the MMP-1 gene was investigated by Lin 
et al. (14) and Cao and Li (9), who have correlated the 
Insertion/Deletion (-1607 2G/1G) polymorphism in the 
promoter region of this gene and the OSCC. Lin et al. 
(14) concluded that 2G genotype in MMP-1 promoter 
could be a risk factor for developing OSCC, since this 
polymorphism was observed with a higher frequency 
in OSCC cases compared with controls. Similarly, Cao 
and Li (9) verified that an increased prevalence of the 
MMP-1 2G/2G genotype in patients with OSCC indi-
cates that this MMP-1 polymorphism confers an increa-
sed risk for OSSC. The results showed that the indivi-
duals with 2G/2G genotype seem to be 2.5 times more 
likely to develop the OSCC than those who were 1G/2G 
or 1G/1G.  Nevertheless, none of these studies (9,14) 
have found statistically significant association between 
MMP-1 genotype in OSCC patients and clinicopatholo-
gical parameters.
- MMP-2 gene polymorphism
In MMP-2 gene, a functional single nucleotide, cytosine 
(C) to thymine (T), polymorphism (-1306 C/T) has been 
reported (30). It seems that CC genotype may be asso-
ciated with the high transcriptional and enzyme activity 
of MMP-2, and eventually affect individual susceptibi-
lity to neoplasms (31). Subjects with the CC genotype 
have been related to increased risk for developing lung 
cancer (32), gastric cardia adenocarcinoma (33) and 
breast cancer (20) compared with those with the CT or 
TT genotype.
Similarly, Lin et al. (31) have verified that patients ca-
rrying CC genotype also present increased risk for de-
veloping oral cancer when comparing with CT or TT 
genotype. However, the genotype CC was not correlated 
to advanced clinical stage of OSCC cases. 
- MMP-3 gene polymorphism
A variant in the promoter of the MMP-3 gene has been 
identified (34) and characterized by one allele having 
five adenosines (5A) and the other allele having six 
adenosines (6A), located at position -1171 (35). The 5A 
allele seems to present a higher promoter activity than 
the 6A allele (35) and in breast cancer the frequency of 
5A allele is likely to be higher in patients than in controls 
(17). Furthermore, the presence of 5A genotype may be 
linked to a higher risk for metastasizing among breast 
cancer (17,36) and esophageal squamous cell carcinoma 
patients (37). In addition, smokers with at least one 5A 
allele have a significantly increased risk of esophageal 
squamous cell carcinoma, compared with 6A homo-
zygotes (37). 
However, in oral cancer, the study of the functional 
nucleotide polymorphism of MMP-3 promoter (-1171 
5A/6A) showed that this polymorphism is not a risk 
factor for oral carcinogenesis (25). Similarly, it was not 
found significant difference for the MMP-3 genotype 
in patients with renal cell carcinoma (19), esophageal 
squamous cell carcinoma (37) and gastric cardiac adeno-
carcinoma (37) when compared to controls individuals.
- MMP-9 gene polymorphism
It was reported a functional C to T single nucleotide po-
lymorphism at position -1562 in
the MMP-9 promoter, where the T allele was described 
to have a higher activity than the C allele (38). This 
DNA modification has been studied in different cancers, 
such as breast (18, 24), gastric (21) and renal carcinoma 
(23); however, the results are still controversial. In gas-
tric cancer, T allele in the MMP-9 promoter is associated 
with the invasive phenotype (21), on the other hand, this 
polymorphism may not be associated with the occurren-
ce of breast (18,24) and renal cancer (23).
In oral oncogenesis, it was reported that the MMP-9 
polymorphism (-1562 C/T) presents a strong associa-
tion with increased risk for developing oral cancer in a 
subset of the general population (39). The higher gene 
expression of MMP-9 was conferred by the T allele and 
the carriers of this nucleotide presented an increased risk 
for developing OSCC only in initial stages, but not in 
advanced ones (39).
Investigating whether this MMP-9 polymorphism could 
influence the risk of areca associated oral cancers, it was 
seen that this DNA modification was linked with OSCC 
risk only in younger areca chewers (40). These results 
illustrate the great importance of genetic association stu-
dies, which may result in preventive measures safeguar-
ding the health status and lives of some individuals at 
risk in the general population (39).
- MMPs research expectations
It is important to say that the MMP gene polymorphisms 
research is certainly beginning and some results are still 
controversial due to some important different factors as 
race, age and type of cancer. Despite these facts, it is be-
lieved that in the future, analyses using polymorphisms, 
will not only identify individual variations within disea-
se comparisons, but will also identify human genetic 
variations, such as how each person responds to certain 
therapy. Therefore, this can intensely improve the un-
derstanding of risk factors, chemoprevention, diagnosis 
and treatments of oral cancer (2).
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Conclusion
To sum up briefly, many researches have been aiming to 
understand the real role of MMPs, phenotypic and geno-
typically, in oral cancer progress. One important tool is 
the DNA analysis, whereby the researchers have inves-
tigated the hypothesis that MMPs gene polymorphisms 
might be related to oral cancer development. Although 
further studies are needed, it is aspired that, in the future, 
it could be possible to find an oral cancer high risk indi-
vidual and try to predict the disease development.
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